Onco Actu du 13 décembre 2016

	3.1 Tabac
Marijuana is now more popular among teens than tobacco or e-cigarettes [STAT] “Now we have more teenagers smoking marijuana than cigarettes,” Dr. Nora Volkow, the director of the National Institute on Drug Abuse, said in an interview. “If you ask if they smoke, they think you mean marijuana,” she said.
	3.1.1 Tabac - e-cigs
E-cigarette use falls among teens for the first time, study finds [LA Times] This year, 26.6% of students said they had tried the devices at least once in their lives, and 9.9% had used them within 30 days of being surveyed, according to the new Monitoring the Future report from the University of Michigan. Last year, those figures were 29.9% and 12.8%, respectively.
	5. Traitements
Drug combinations that help breast cancer patients discovered using data science [Stanford Medicine] The research appears in the Journal of the American Medical Informatics Association.
	5.12 Immunothérapies
BMS' Opdivo jumps back into pharma's top 3 TV ad spenders for November [FiercePharma] The most-run November ad, which describes Opdivo as the “most prescribed immunotherapy,” originally debuted in May and BMS shelled out $20.7 million in November on it, for a total of $54.9 million on TV airings so far, according to data from iSpot.tv.
Pfizer bankrolls an oncolytics biotech upstart with an eye on a future buyout [EndPoints] Pfizer is also paying for the R&D work at the company over the next three years, as Ignite looks to jump into a wave of up and coming biotechs where are hurrying along next-gen oncolytic vaccines aiming at surpassing the pioneering Imlygic (T-Vec), marketed by Amgen. A bunch of these startups are pairing up with checkpoint inhibitors, a fact that wasn’t lost on Pfizer as it seeks the 4th OK of a checkpoint drug.
	5.12.2 Immunothérapies - CAR-T
Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine [Kite] The research, led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI's Center for Cancer Research, and a scientific collaborator with Kite, describes a patient with KRAS mutant metastatic colorectal cancer who was successfully treated with T cells that are reactive to KRAS G12D mutation. This work follows previously reported treatment of a patient with advanced cholangiocarcinoma with T cells targeting a mutated erbb2 interacting protein.
	5.2 Pharma
Seattle Genetics chalks up first clinical trial success in solid tumors [FierceBiotech] The drug consists of a LIV-1-targeted monoclonal antibody linked to the cell-killing payload monomethyl auristatin E, and is one of four candidates Seattle Genetics has in clinical trials for solid tumors.
	5.2.3 Pharma - économie
Supreme Court declines to hear biologic drug patent fight [Reuters] The justices opted not to take up Apotex Inc's appeal of a July federal appeals court ruling that could delay the Canadian generic drug maker's launch of so-called biosimilar versions of California-based Amgen Inc's Neulasta, used to fight infection in cancer patients.
	5.3 Traitements - FDA, EMA, NICE...
Scottish Medicines Consortium approves Sanofi's prostate cancer drug [Pharmafile] A taxane chemotherapy solution, Jevtana (cabazitaxel) can be used when cancer cells prove resistant to docetaxel and kills cancer by inhibiting cell division. The approval decision was based on data which showed that patients treated with the drug experienced extended survival when compared to an active rival treatment.
Faster Information from FDA Means Improved Drug Safety for Patients [FDA Voice] Our improved Drug Safety Labeling Changes Program enables FDA to post the latest safety information about a medicine almost at the same time we approve a change, as opposed to once a month.
	5.4 Traitements - Economie
Once-spurned cancer drugs win NICE's favor with—no surprise—'sensible pricing' [FiercePharma] Nowadays, many companies know what they have to do to win coverage in the U.K. and realize they have to “go through it,” King’s College London Institute of Cancer Policy director Richard Sullivan recently told The BMJ. That includes pricing meds “where they know [they] will meet NICE’s threshold.”
Scottish breast cancer patients denied drug approved for English NHS [The Telegraph] Campaigners said the Scottish Medicines Consortium’s (SMC) decision not to accept Perjeta - also known as pertusumab - had created the "ultimate postcode lottery". The agency, which decides which new drugs should be provided on the NHS, said it had rejected the treatment over concerns about its long-term survival benefits and not because of cost.
	5.7.1 SABCS-communiqués
Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS [Merck] Findings presented during the 2016 San Antonio Breast Cancer Symposium (SABCS) were based on interim data from 39 evaluable patients and showed an overall response rate (ORR) of 33.3% (n=13/39; 95% CI, 19.5-48.1), with one complete response and 12 partial responses.
	5.7.2 SABCS-divers
Untreated Late Effects of Breast Cancer Care Increase Depression and Anxiety Among Survivors, Penn Study Shows [Penn Medicine] The researchers suggest that when extended to the larger breast cancer survivor population, more than 1,300,00 breast cancer survivors could be experiencing at least three specific symptoms for which they need assistance.
	5.9 AACR
AACR Receives $1.125 Million NCI Grant to Continue Clinical Trials Workshop [AACR] Nearly 2,100 clinical fellow and junior faculty clinical researchers have attended the Workshop over the past 21 years.
	6.1 Observation
Social support tied to better breast cancer outcomes [Reuters] For the new study, published December 12th in Cancer, the researchers analyzed data collected from 9,267 women in the United States and China within two years of their breast cancer diagnosis.
	6.10.1 Politiques (USA)
Trump is considering a radical to lead FDA. That’s dangerous for public health [STAT] But you may ask, “What’s the harm? If the drug is safe, why not let people try it?” Well, most drugs are not safe, actually. They’re approved because clinical trials have shown that on balance, they help more than they hurt. Moreover, this assumption ignores the immense cost that such a scheme could impose on the health care system.
	6.6 Publications
Dear peer reviewer, you stole my paper: An author’s worst nightmare [Retraction Watch] “Deeply disturbing,” “heinous intellectual theft,” erosion of the “public’s trust in medical research:” These are just a few words used to describe a rare type of plagiarism reported in this week’s Annals of Internal Medicine.
	6.7 DMP, Big Data & applis
Watson and Pfizer [In the Pipeline] From what I understand, a key feature to any machine-learning approach is having negative data for it to work with as well as positive (which makes sense). The problem is, the literature is extremely sparse on negative results.